Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

被引：20
|
作者：
Nathwani, Nitya [1 ]
Krishnan, Amrita Y. [1 ]
Huang, Qin [2 ]
Kim, Young [2 ]
Karanes, Chatchada [1 ]
Smith, Eileen P. [1 ]
Forman, Stephen J. [1 ]
Sievers, Eric [3 ]
Thomas, Sandra H. [1 ]
Chen, Robert W. [1 ]
机构：
[1] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA
[3] Seattle Genet, Bothell, WA USA
来源：
LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 10期
关键词：
STEM-CELL TRANSPLANTATION; DISEASE; TUBULIN; TRIAL;
D O I：
10.3109/10428194.2012.666543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2051 / 2053
页数：3
相关论文
共 50 条
  • [1] PERSISTENCE OF CD30 EXPRESSION IN CD30-POSITIVE LYMPHOMAS FOLLOWING TREATMENT WITH BRENTUXIMAB VEDOTIN (SGN-35)
    Chen, W.
    Nathwani, N.
    Forman, S.
    Popplewell, L.
    Krishnan, A.
    Gomez, C.
    Karanes, C.
    Smith, E.
    Farol, L.
    Thomas, S.
    Kim, Y.
    HAEMATOLOGICA, 2012, 97 : 81 - 82
  • [2] Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
    Alperovich, Anna
    Younes, Anas
    CANCER JOURNAL, 2016, 22 (01): : 23 - 26
  • [3] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
    Younes, Anas
    Bartlett, Nancy L.
    Leonard, John P.
    Kennedy, Dana A.
    Lynch, Carmel M.
    Sievers, Eric L.
    Forero-Torres, Andres
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19): : 1812 - 1821
  • [4] Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma
    Sasse, Stephanie
    Rothe, Achim
    Goergen, Helen
    Eichenauer, Dennis A.
    Lohri, Andreas
    Kreher, Stephan
    Jaeger, Ulrich
    Bangard, Christopher
    Kuhnert, Georg
    Boell, Boris
    von Tresckow, Bastian
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2144 - 2148
  • [5] Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
    Jagadeesh, Deepa
    Horwitz, Steve
    Bartlett, Nancy L.
    Kim, Youn
    Jacobsen, Eric
    Duvic, Madeleine
    Little, Meredith
    Trepicchio, William
    Fenton, Keenan
    Onsum, Matthew
    Lisano, Julie
    Advani, Ranjana
    ONCOLOGIST, 2022, 27 (10): : 864 - 873
  • [6] Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
    Gualberto, Antonio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) : 205 - 216
  • [7] Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL)
    Bhatt, Shruti
    Ashlock, Brittany
    Natkunam, Yaso
    Ramos, Juan Carlos
    Mesri, Enrique
    Lossos, Izidore S.
    BLOOD, 2011, 118 (21) : 1592 - 1592
  • [8] Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Klasa, Richard
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2010, 116 (21) : 128 - 129
  • [9] Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series
    Gopal, A. K.
    Ramchandren, R.
    Berryman, R. B.
    Advani, R. H.
    Chen, R.
    Smith, S.
    Cooper, M.
    Engert, A.
    Matous, J.
    Zain, J.
    Grove, L. E.
    Hunder, N. N.
    O'Connor, O. A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S36 - S36
  • [10] Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
    Forero-Torres, Andres
    Berryman, R. Brian
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Chen, Robert W.
    Fanale, Michelle A.
    Gopal, Ajay K.
    O'Connor, Owen A.
    Olshefski, Randal
    Smith, Scott E.
    Grove, Laurie E.
    Matous, Jeffrey
    BLOOD, 2011, 118 (21) : 1585 - 1586
12345